来自MSN3 小时
Triple Therapy in Metastatic CRC With BRAF Mutations: The New Standard of Care?
First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...
Cure Today18 小时
The BREAKWATER Trial Explores Braftovi, Erbitux and Chemo in BRAF V600E+ mCRC
Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...
PipelineReview.com1 小时
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with ...
NEW YORK, NY, USA I5, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® ...
News Medical on MSN6 小时
Triple therapy shows strong response in BRAF V600E mutant metastatic colorectal cancer
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
Le Lézard7 小时
Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...
Le Lézard9 小时
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, ...